X55c46455.46e3.40c2.ba37.333e25431e91
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- INTERFERON_GAMMA_RESPONSE+0.340
- MYC_TARGETS_V2+0.320
- INTERFERON_ALPHA_RESPONSE+0.290
- SPERMATOGENESIS+0.260
- KRAS_SIGNALING_DN+0.250
- ALLOGRAFT_REJECTION+0.230
- MTORC1_SIGNALING+0.220
Top 10 suppressed
- TGF_BETA_SIGNALING-0.440
- PROTEIN_SECRETION-0.400
- OXIDATIVE_PHOSPHORYLATION-0.330
- UV_RESPONSE_DN-0.260
- KRAS_SIGNALING_UP-0.240
- HEDGEHOG_SIGNALING-0.230
- P53_PATHWAY-0.220
- TNFA_SIGNALING_VIA_NFKB-0.220
- WNT_BETA_CATENIN_SIGNALING-0.220
- APICAL_JUNCTION-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 58c2404d-b213-4a7f-a8fc-11081a88091b | — | — | 0.738 |
| 2 | SRR26320078 | — | — | 0.717 |
| 3 | SRR1516081 | — | — | 0.695 |
| 4 | MNG91 | — | — | 0.694 |
| 5 | TCGA-AO-A1KQ-01A-11R-A13Q-07 | — | B | 0.690 |
| 6 | TCGA-A2-A4S3-01A-21R-A266-07 | — | B | 0.686 |
| 7 | SRR33346961 | — | — | 0.685 |
| 8 | TCGA-NC-A5HL-01A-11R-A26W-07 | — | cohortSQ2 | 0.681 |
| 9 | DRR168510 | — | — | 0.673 |
| 10 | TCGA-A8-A08B-01A-11R-A00Z-07 | — | C | 0.671 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |